| Autor: |
Zelada H; Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA., Perez-Guzman MC; Internal Medicine Division of Endocrinology, Centro Médico ABC, Mexico City, Mexico., Chernavvsky DR; Center for Diabetes Technology, University of Virginia, Charlottesville, Virginia, USA., Galindo RJ; Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine. Miami, Florida, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Endocrine connections [Endocr Connect] 2023 Sep 25; Vol. 12 (10). Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023). |
| DOI: |
10.1530/EC-23-0180 |
| Abstrakt: |
Over the last few years, several exciting changes in continuous glucose monitoring (CGM) technology have expanded its use and made CGM the standard of care for patients with type 1 and type 2 diabetes using insulin therapy. Consequently, hospitals started to notice increased use of these devices in their hospitalized patients. Furthermore during the coronavirus disease 2019 (COVID) pandemic, there was a critical need for innovative approaches to glycemic monitoring, and several hospitals started to implement CGM protocols in their daily practice. Subsequently, a plethora of studies have demonstrated the efficacy and safety of CGM use in the hospital, leading to clinical practice guideline recommendations. Several studies have also suggested that CGM has the potential to become the standard of care for some hospitalized patients, overcoming the limitations of current capillary glucose testing. Albeit, there is a need for more studies and particularly regulatory approval. In this review, we provide a historical overview of the evolution of glycemic monitoring in the hospital and review the current evidence, implementation protocols, and guidance for the use of CGM in hospitalized patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
